Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Luminex Corporation

Luminex develops, manufactures, and markets biological testing technologies with applications in clinical diagnostics... read more Featured Products: More products

Download Mobile App




Bead-Based Immunoassay Developed to Measure Vimentin Autoantibodies

By LabMedica International staff writers
Posted on 01 Jul 2014
Print article
Luminex FlexMap 3D
Multiplex assay (Photo courtesy of Luminex - A Diasorin Company)
An immunobead assay has been developed to quantitate circulating levels of vimentin antibodies, and, to test the feasibility of these autoantibodies as a biomarker for clinical diagnosis.

Vimentin is an intermediate filament protein generally expressed in the cytosol of many adult cell types, including leukocytes, fibroblasts and endothelial cells. Several tissue and/or injury-specific isoforms of vimentin are known to exist that may trigger autoimmune responses due to aberrant structural or conformational variations.

Scientists at the Rush University Medical Center (Chicago, IL, USA) evaluated the efficacy of the newly developed assay on discarded serum samples collected from 51 renal transplant patients with allograft dysfunction and compared the results with control specimens from 20 age and gender matched control individuals.

Magplex Microspheres (Luminex Corporation; Austin, TX, USA) were used in the development of this vimentin autoantibody assay and were processed in batches of 106 beads. Recombinant human vimentin (R&D Systems, Minneapolis, MN, USA) were added to the MagPlex beads and serum samples were processed. Assay performance and microsphere validation was accomplished by reading on a Luminex FlexMap 3-D system with a minimum of 50 bead reads per well. Median fluorescence intensity (MFI) values were reported for the conditions to permit the evaluation of coupling efficiency and preliminary evaluation of an assay range.

Preliminary evaluation of the assay demonstrates significantly higher circulating levels of anti-vimentin antibodies in 51 cases of renal allograft rejection relative to 20 cases of age-matched controls. From repeated testing of three distinct batches of assays provide assay range parameters of 0.18–15 μg/mL, median inter-assay recovery parameter was within 1% of completion, and interassay variation was at 7%.

The authors concluded that their direct capture assay for vimentin autoantibodies was successfully developed and analytically validated. Preliminary evaluation of this assay against patient materials was promising and justifies additional testing with larger cohorts in future studies. The study was published in the May 2014 issue of Journal of Immunological Methods.

Related Links:

Rush University Medical Center
Luminex Corporation
R&D Systems


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.